Spots Global Cancer Trial Database for Imatinib Mesylate in Patients With Refractory Desmoplastic Small Round Cell Tumors
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Imatinib Mesylate in Patients With Refractory Desmoplastic Small Round Cell Tumors
Official Title: Open-label Trial of Imatinib Mesylate in Patients With Refractory Desmoplastic Small Round Cell Tumors (DSRCT) Expressing PDGF-R
Study ID: NCT00417807
Interventions
Study Description
Brief Summary: An open-label, non-comparative study conducted to investigate the activity and safety of imatinib mesylate in refractory desmoplastic small round cell tumors expressing PDGF-R. Patients will be treated up to 12 months, or to disease progression. Tumor will be evaluated according to Recist criteria
Detailed Description:
Eligibility
Minimum Age: 16 Years
Eligible Ages: CHILD, ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Novartis Investigative Site, Ivrea, , Italy
Novartis Investigative Site, Milano, , Italy
Novartis Investigative Site, Napoli, , Italy
Novartis Investigative Site, Padova, , Italy
Novartis Investigative Site, Ravenna, , Italy
Novartis Investigative Site, Rozzano, , Italy
Novartis Investigative Site, Torino, , Italy
Novartis Investigative Stie, Vatania, , Italy
Contact Details
Name: Novartis Pharmaceuticals
Affiliation: Novartis Pharmeceuticals
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
